The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
Open accessAbstract
Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized controlled trial was conducted between February 1990 and February 1998 at Osaka University Hospital. 91 consecutive patients <71 years old (mean age 62) with unresectable HCC were enroled in this study. 8 patients were withdrawn because of progressive liver dysfunction; 83 patients were randomized to standard treatment with or without pravastatin. All patients underwent transcatheter arterial embolization (TAE) followed by oral 5-FU 200 mg(-1)d for 2 months. Patients were then randomly assigned to control (n = 42) and pravastatin (n = 41) groups. Pravastatin was administered at a daily dose of 40 mg. The effect of pravastatin on tumour growth was assessed by ultrasonography. Primary endpoint was death due to progression of HCC. The duration of pravastatin administration was 16.5 +/- 9.8 months (mean +/- SD). No patients in either group were lost to follow-up. Median survival was 18 months in the pravastatin group versus 9 months in controls (P = 0.006). The Cox proportional hazards model showed that pravastatin was a significant factor contributing to survival. Pravastatin prolonged the survival of patients with advanced HCC, suggesting its value for adjuvant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?
Juma, S., Imrhan, V., Vijayagopal, P., & Prasad, C. (2014) · Lifestyle Genomics · doi:10.1159/000370213 · Cited by 1,891
Hepatic artery embolization in 120 patients with unresectable hepatoma.
Yamada, R., Sato, M., Kawabata, M., Nakatsuka, H., Nakamura, K., & Takashima, S. (1983) · Radiology · doi:10.1148/radiology.148.2.6306721 · Cited by 993
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor
Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., & Gibbs, J. B. (1993) · Science · doi:10.1126/science.8316833 · Cited by 579
Hepatitis C and hepatocellular carcinoma
Di Bisceglie, A. M. (1997) · Hepatology · doi:10.1002/hep.510260706 · Cited by 558
Cited by
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Marelli, L., Stigliano, R., Triantos, C., Senzolo, M., Cholongitas, E., Davies, N., Tibballs, J., Meyer, T., Patch, D. W., & Burroughs, A. K. (2007) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-006-0062-3 · Cited by 791
Statin Use and Reduced Cancer-Related Mortality
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1214827 · Cited by 720
Wong, W. W.-L., Dimitroulakos, J., Minden, M., & Penn, L. (2002) · Leukemia · doi:10.1038/sj.leu.2402476 · Cited by 578
The Risk of Cancer in Users of Statins
Graaf, M. R., Beiderbeck, A. B., Egberts, A. C. G., Richel, D. J., & Guchelaar, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.027 · Cited by 528
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 451
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Ahern, T. P., Pedersen, L., Tarp, M., Cronin-Fenton, D. P., Garne, J. P., Silliman, R. A., Sorensen, H. T., & Lash, T. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr291 · Cited by 387
Mo, H., & Elson, C. E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900701 · Cited by 340
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
Tsan, Y.-T., Lee, C.-H., Wang, J.-D., & Chen, P.-C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0917 · Cited by 294
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Caldwell, R. B., Bartoli, M., Behzadian, M. A., El‐Remessy, A. E. B., Al‐Shabrawey, M., Platt, D. H., & Caldwell, R. W. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.415 · Cited by 293
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 291
El–Serag, H. B., Johnson, M. L., Hachem, C., & Morgana, R. O. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.053 · Cited by 291
Edeline, J., Boucher, E., Rolland, Y., Vauléon, E., Pracht, M., Perrin, C., Le Roux, C., & Raoul, J. (2012) · Cancer · doi:10.1002/cncr.26255 · Cited by 275
Statins and hepatotoxicity: Focus on patients with fatty liver†
Chalasani, N. (2005) · Hepatology · doi:10.1002/hep.20671 · Cited by 265
Statins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
Perumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3821-7 · Cited by 111
Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor
Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1951 · Cited by 101
Pravastatin-loaded chitosan nanoparticles: Formulation, characterization and cytotoxicity studies
Badran, M. M., Harisa, G. I., AlQahtani, S. A., Alanazi, F. K., & Zoheir, K. M. A. (2016) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2016.01.004 · Cited by 33
Biological consequences of statins in Candida species and possible implications for human health
Wikhe, K., Westermeyer, C., & Macreadie, I. G. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351529 · Cited by 31
Benjamin, D. J., Haslam, A., & Prasad, V. (2024) · Cancer Medicine · doi:10.1002/cam4.7049 · Cited by 30
Rimpelová, S., Kolář, M., Strnad, H., Ruml, T., Vítek, L., & Gbelcová, H. (2021) · Molecules · doi:10.3390/molecules26123528 · Cited by 8
Metadata
- Authors
- Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., & Matsuzawa, Y.
- Venue
- British Journal of Cancer
- Published
- 2001
- Volume
- 84
- Issue
- 7
- Pages
- 886-891
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2049659810
- Cited by
- 354
- References
- 21
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.